Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
Authors
Keywords
-
Journal
Emerging Microbes & Infections
Volume 12, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2022-11-29
DOI
10.1080/22221751.2022.2151381
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
- (2022) Mayan Teles et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies
- (2022) Zahra Yousefi et al. CURRENT MICROBIOLOGY
- Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
- (2022) YangYang et al. JOURNAL OF INFECTION
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2022) Juan Manuel Carreño et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
- (2022) Paul R. Wratil et al. NATURE MEDICINE
- Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
- (2022) Chengbao Ma et al. Emerging Microbes & Infections
- The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
- (2022) Xinrong Zhou et al. Emerging Microbes & Infections
- Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
- (2022) Yang Yang et al. Nature Microbiology
- Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
- (2022) Chang Kyung Kang et al. BMC Medicine
- Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- (2022) Pyoeng Gyun Choe et al. JOURNAL OF INFECTIOUS DISEASES
- A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients
- (2022) Ilies Benotmane et al. KIDNEY INTERNATIONAL
- Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
- (2022) Thiago Cerqueira-Silva et al. LANCET INFECTIOUS DISEASES
- Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
- (2022) Yinon M. Bar-On et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
- (2022) Ori Magen et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies
- (2022) Sabrina Lusvarghi et al. Science Translational Medicine
- Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study
- (2022) Lixue Huang et al. Lancet Respiratory Medicine
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
- (2022) Aekkachai Tuekprakhon et al. CELL
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
- (2022) Yunlong Cao et al. NATURE
- Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
- (2022) John E. Bowen et al. SCIENCE
- Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
- (2021) Richard A. Urbanowicz et al. Science Translational Medicine
- Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
- (2021) Cesheng Li et al. Nature Communications
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
- (2021) Markus Hoffmann et al. CELL
- Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
- (2021) Carolina Lucas et al. NATURE
- Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
- (2021) Margherita Rosati et al. Frontiers in Immunology
- Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant
- (2021) Nassim Kamar et al. JAMA Network Open
- Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country
- (2021) Alejandro Macchia et al. JAMA Network Open
- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
- (2020) Juanjuan Zhao et al. CLINICAL INFECTIOUS DISEASES
- IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
- (2020) Andrea Padoan et al. CLINICA CHIMICA ACTA
- Kinetics of viral load and antibody response in relation to COVID-19 severity
- (2020) Yanqun Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
- (2020) Gregory A Poland et al. LANCET
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
- (2020) Angkana T. Huang et al. Nature Communications
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More